Aplasia Cutis Congenita (ACC) with Autosomal Recessive Disease

Aplasia Cutis Congenita (ACC) with Autosomal Recessive Disease means a baby is born with a patch where skin did not form. It is present at birth. The patch may look like a shallow wound, a thin shiny membrane, or a small scar. It most often sits on the scalp, especially on the top (the “vertex”). But it can appear on the trunk or limbs too. Sometimes the skin only is missing. Sometimes deeper tissue like the skull bone is also thin or missing. Most small patches heal with simple care. Large or deep areas need careful protection and sometimes surgery. ACC can happen by itself (nonsyndromic) or as part of a genetic syndrome. Some of these syndromes are autosomal recessive, which means a child is affected when they inherit a non-working copy of the gene from both parents. DermNet®+2MedlinePlus+2

Aplasia cutis congenita (ACC) means a baby is born with one or more small or large patches of skin missing. The skin gap may involve only the top layer (epidermis) or can go deeper into the dermis and the fat layer, and sometimes even down to bone on the scalp. Most lesions are small, usually on the top of the head (scalp), and heal over weeks with careful wound care. ACC can occur by itself or as part of a genetic condition. Some forms are autosomal recessive, which means a child inherits two nonworking copies of a gene (one from each parent). Recessive examples include epidermolysis bullosa with congenital absence of skin (EB-CAS, historically “Bart syndrome”) and some families with Adams–Oliver syndrome due to genes like DOCK6 or EOGT. In these syndromes, ACC is one sign among others (such as skin fragility or limb differences). Management focuses on safe healing, preventing infection or bleeding, and checking for deeper defects when the lesion is large, midline, or overlying major blood vessels. NORD+3NCBI+3NORD+3

In many babies, the exact cause is mixed. Genes, the placenta, blood flow, infections, and some medicines taken in pregnancy may all play a role. Doctors group ACC into types based on where it appears, what it looks like, and what other features are present. Medscape+1

Other names

People may use these names for the same idea, or for closely related patterns:

• Cutis aplasia (another way to say “missing skin”). GOSH Hospital site

• Congenital absence of skin (plain term). DermNet®

• Bart syndrome or epidermolysis bullosa with congenital absence of skin (a recessive/mechanobullous condition with ACC and fragile skin/blisters). DermNet®+1

• Adams–Oliver syndrome (AOS) (ACC of scalp with limb defects; has both dominant and recessive forms). PubMed+1

• Setleis syndrome (focal facial dermal dysplasia; bitemporal ACC-like lesions; often recessive). (Summarized from clinical genetics literature.)

• Nonsyndromic ACC (ACC without other anomalies). MedlinePlus

Types

Doctors often use a practical system that looks at location, number, depth, and associated features/syndromes. Here is a simple way to think about it:

1. Isolated scalp patch(es): single or few lesions on the vertex. Usually small and superficial; may have a membrane or scar. DermNet®

2. Non-scalp lesions: on trunk or limbs; may align with “Blaschko lines” (skin development lines). Medscape

3. ACC with underlying bone defect: scalp lesion plus thin or absent skull bone beneath; needs imaging to check the skull and dura. NCBI

4. ACC with limb defects: classic for Adams–Oliver syndrome; look for short or missing fingers/toes or terminal limb reduction. (Includes recessive gene forms such as DOCK6/EOGT.) PubMed+1

5. ACC with blistering and nail changes: typical Bart syndrome (ACC + epidermolysis bullosa); usually autosomal recessive. DermNet®+1

6. ACC in facial/temporal areas: can resemble Setleis/focal facial dermal dysplasia. (Consensus clinical descriptions.)

7. ACC as part of other rare associations: for example, very rare ACC-intestinal lymphangiectasia association. Orpha

The exact historical “type I–IX” lists vary between sources; the practical focus is on where the skin is missing, how deep it is, and what other signs guide testing and treatment. Medscape

Causes

ACC can have many causes. Below are 20 recognized or plausible drivers, grouped for clarity. Each item includes a plain explanation.

Genetic—autosomal recessive syndromes or genes

1. Bart syndrome (EB with ACC): recessive skin-fragility disorder; blisters form easily; ACC patches (often on legs or feet) may be present at birth. DermNet®+1

2. Adams–Oliver syndrome, recessive forms (e.g., DOCK6, EOGT): reduced blood vessel signaling and skin/limb development cause scalp ACC plus limb defects. PubMed+1

3. Setleis syndrome (focal facial dermal dysplasia): often recessive; causes temple skin defects that look like healed scars or ACC-like patches. (Summarized from clinical genetics literature.)

4. Recessive EB subtypes (e.g., COL7A1, LAMB3/LAMC2): severe blistering can present with localized areas where skin is absent at birth. (Dermatology/EB reviews broadly support this mechanism.)

5. Rare ACC gene defects (e.g., BMS1 ribosome biogenesis): families with ACC have been linked to BMS1 variants affecting skin development. ScienceDirect+1

Placental / vascular factors

1. Placental infarction or thrombosis: reduced blood flow to a small fetal skin area can stop skin from forming there. NCBI
2. Amniotic bands or early membrane rupture: strands can compress the skin and cause focal absence. (General ACC reviews.) Medscape
3. Vascular disruption in utero: small vessel problems during a key time window can leave a skin “gap.” Medscape

Teratogens and exposures

1. Methimazole (antithyroid drug) exposure in early pregnancy: linked to scalp ACC and other anomalies in
2.  Misoprostol exposure (less consistent): vascular disruption has been suggested in case series (not all sources agree). (Inferred from teratogen discussions in clinical reviews.)
3. Cocaine or vascular-active substances: may reduce fetal skin blood flow; evidence is mainly case-based. (Clinical review summaries.)

Infections and inflammation

1. Congenital viral infections (e.g., varicella, HSV): localized skin necrosis during fetal life can heal as ACC. (ACC reviews note intrauterine infections.) NCBI
2. Maternal fever with severe fetal inflammatory response: rarely, this can damage tiny skin vessels. (General mechanism discussion in reviews.)

Mechanical / physical factors

1. Fetal trauma in utero: pressure or instrument injury can create a focal defect that looks like ACC at birth. Medscape
2. Twin phenomena (e.g., “fetus papyraceus”): vascular sharing or loss of a co-twin can cause ischemic skin loss. (Clinical review concepts.)

Chromosomal / multisystem contexts

1. Chromosomal disorders (e.g., Trisomy 13): ACC can be one feature in a complex anomaly pattern. (Commonly noted in reviews.)
2. Scalp-ear-nipple syndrome (usually AD, listed here for completeness): includes scalp ACC-like nodules; shows that ACC spans many inheritance types. MedlinePlus

Idiopathic or isolated

1. Nonsyndromic ACC (isolated): cause unknown; likely a mix of genetic and environmental factors; usually has a good outcome. MedlinePlus
2. Familial ACC with unclear gene: strong family history suggests a gene not yet identified. (Discussed in reviews.)
3. Post-inflammatory “healed” prenatal lesion: some patches are already scar-like at birth, showing they formed earlier and then healed. MedlinePlus

Common symptoms and signs

1. Visible missing skin patch at birth: round or oval area, often on the scalp; size varies from a few millimeters to several centimeters. DermNet®

2. Thin shiny membrane covering the site, or a crust: shows partial healing. NCBI

3. Hairless scar later in infancy: healed ACC does not grow hair. DermNet®

4. Bleeding or oozing in the first days if the area is open. (General neonatal wound care principles.)

5. Underlying bone thinning or gap under a scalp lesion (some cases). NCBI

6. Limb changes (short or missing fingers/toes) in AOS. PubMed

7. Blistering skin and nail problems in Bart syndrome (EB). DermNet®

8. Feeding issues or infection risk if the wound is large. (Neonatal care summaries.)

9. Tenderness at the site at first; pain usually improves as healing occurs. (Clinical course.)

10. Sun sensitivity of the area after healing; needs protection. (Dermatology aftercare norms.)

11. Cosmetic concern because of hairless scalp scar. DermNet®

12. Head shape asymmetry if bone beneath is involved. (Imaging/literature notes on osseous defects.)

13. Vascular anomalies (AOS) like cutis marmorata or heart issues in some patients. PubMed

14. Superinfection of the open area if not protected (redness, pus, fever). (Standard wound-infection signs.)

15. Family recurrence in genetic forms (recessive risk 25% for each pregnancy when both parents are carriers). (Basic genetics principle.)

Diagnostic tests

A) Physical examination (bedside)

1. Full skin exam: record size, number, depth, and location of the ACC patch; check for blisters, nail changes, and other lesions. This guides risk and next tests. Medscape

2. Head and fontanel exam: feel for bone gaps beneath scalp lesions; large, deep, or pulsatile defects need imaging. NCBI

3. Limb exam: look for terminal limb differences (AOS clue). PubMed

4. Nail and mucosa exam: nail dystrophy and mouth blisters suggest EB/Bart syndrome. DermNet®

5. System exam (heart, abdomen, eyes, face): screens for syndromic features and other organ issues. (Syndrome work-up standard.)

B) Manual/clinical bedside tests and measurements

1. Serial wound measurements (length × width; photographs): track healing and spot infection early. (Wound-care standard practice.)
2. Gentle probe depth check (by specialist only): helps judge if bone or dura might be exposed (sterile technique). (Neonatal surgical practice.)
3. Blood pressure, perfusion checks, and limb pulses: look for vascular clues in AOS. (AOS vascular focus.) PubMed
4. Growth and head circumference: large skull defects merit closer neuro follow-up. (General pediatrics principle.)
5. Family pedigree and carrier risk discussion: manual pedigree drawing clarifies recessive risk (25%) and testing needs. (Clinical genetics standard.)

C) Laboratory and pathological tests

1. Genetic testing panel / exome for ACC syndromes: includes DOCK6, EOGT, DLL4, RBPJ, NOTCH1 (AOS), EB genes (COL7A1, LAMB3/LAMC2), and BMS1 where indicated. Confirms recessive forms and guides counseling. ScienceDirect+3PubMed+3PMC+3
2. Targeted EB gene testing when blistering is present (Bart syndrome suspicion). Helps plan skin care and infection prevention. DermNet®
3. TORCH (congenital infection) serology if lesions look infectious in origin or there is maternal history. (ACC reviews mention intrauterine infections.) NCBI
4. Wound swab culture if the site is draining or looks infected, to guide antibiotics. (Neonatal wound care.)
5. Placental pathology (if available): can show infarcts or thrombosis that support a vascular cause. NCBI

D) Electrodiagnostic and physiologic studies

1. Electrocardiogram (ECG) and echocardiography if AOS or cardiac signs exist; vascular-heart associations occur in some AOS patients. (AOS literature notes systemic involvement.) PubMed
2. EEG only if seizures or neurologic events occur, especially with large skull defects; checks brain activity. (Standard neurology practice.)
3. Auditory brainstem response (ABR) if ear/temporal lesions or syndromic cues suggest hearing risk; ensures early support. (Newborn screening norms.)

E) Imaging

1. Cranial ultrasound (bedside) or CT/MRI for large or deep scalp lesions to look for bone defects, venous sinuses, or dura exposure; MRI avoids radiation when feasible. NCBI
2. Doppler ultrasound of limbs (if AOS suspected) to assess blood flow and malformations; can guide vascular care. (AOS vascular focus.) PubMed

Non-pharmacological treatments (therapies & other measures)

Each item explains what it is, purpose, and how it helps (mechanism) in simple terms.

1. Gentle wound cleansing and petrolatum
   Purpose: Keep the area clean and moist so new skin can grow.
   Mechanism: Moist wound healing (using plain petrolatum and non-adherent dressings) reduces crusting, protects new cells, and speeds re-epithelialization while lowering infection risk. NCBI+1

2. Non-adherent dressings (silicone mesh, tulle, or hydrogel)
   Purpose: Cover and protect the wound without sticking.
   Mechanism: Maintains a moist environment and provides a barrier to bacteria; atraumatic removal preserves fragile new tissue. NCBI

3. Atraumatic debridement (only if needed)
   Purpose: Remove loose crusts that trap bacteria.
   Mechanism: Gentle lift of nonviable debris allows healthy edges to migrate and close the defect faster; always cautious on neonatal scalp. NCBI

4. Infection surveillance and early intervention
   Purpose: Catch infection before it spreads.
   Mechanism: Daily checks for redness, warmth, pus, or fever enable rapid switch from topical to systemic therapy if needed, preventing cellulitis/sepsis. NCBI

5. Bleeding precautions
   Purpose: Avoid injury to exposed vessels, especially near the sagittal sinus on the scalp.
   Mechanism: Protective dressings and careful handling reduce risk of hemorrhage from fragile tissues or underlying venous sinuses. NCBI

6. Imaging when red flags are present
   Purpose: Look for skull or dural defects in large, midline, or deep scalp lesions.
   Mechanism: Ultrasound/CT/MRI check bone and soft tissue so surgeons can plan repairs if needed. NCBI

7. Sun protection
   Purpose: Prevent sunburn and pigment change on healing skin.
   Mechanism: Hats/shade (sunscreens once age-appropriate) limit UV damage to immature skin. DermNet®

8. Parental education and hands-on training
   Purpose: Empower families to do safe home dressing changes.
   Mechanism: Clear, simple routines reduce complications and improve healing adherence. GOSH Hospital site

9. Pain-minimizing dressing schedules
   Purpose: Reduce discomfort during changes.
   Mechanism: Non-stick dressings + adequate analgesia before changes prevent trauma to new epithelium. NCBI

10. Multidisciplinary care (neonatology, dermatology, genetics, surgery)
    Purpose: Coordinate wound care, genetic testing, and surgical planning.
    Mechanism: Team input ensures timely escalation when lesions are deep or syndromic. NCBI

11. Early genetic counseling/testing when syndromic features exist
    Purpose: Confirm recessive causes (e.g., EB-CAS, recessive AOS) and guide family planning.
    Mechanism: Molecular diagnosis clarifies recurrence risk and tailors care pathways. PMC+1

12. Avoid irritants (fragrances, harsh cleansers)
    Purpose: Protect fragile, developing skin.
    Mechanism: Gentle, pH-balanced cleansing lowers dermatitis and secondary breakdown. DermNet®

13. Nutritional support for wound healing
    Purpose: Ensure enough calories and protein for growth and repair.
    Mechanism: Adequate macronutrients and micronutrients (e.g., zinc, vitamin C as medically indicated) support collagen and keratinocyte function. NCBI

14. Infection control (hand hygiene, clean technique)
    Purpose: Reduce bacterial contamination during home care.
    Mechanism: Handwashing and clean materials lower risk of cellulitis. NCBI

15. Scar management after closure
    Purpose: Improve appearance and flexibility.
    Mechanism: Once healed, gentle massage and silicone gel (when age-appropriate) may soften hypertrophic scarring. NCBI

16. Helmet avoidance early on (unless prescribed)
    Purpose: Prevent pressure and friction over healing scalp.
    Mechanism: Reduces mechanical trauma to the defect. NCBI

17. Prompt care for EB skin fragility (if EB-CAS)
    Purpose: Minimize blistering and secondary erosions beyond ACC area.
    Mechanism: Low-friction handling, soft clothing, and blister lancing protocols prevent spread. DermNet®

18. Cardiac/vascular evaluation when AOS suspected
    Purpose: Identify associated anomalies that can change anesthesia/surgery risks.
    Mechanism: Echocardiography and vascular assessment detect malformations seen in some AOS genotypes. NORD

19. Psychosocial support for families
    Purpose: Manage stress and set expectations for healing and scarring.
    Mechanism: Counseling improves coping and adherence to care routines. GOSH Hospital site

20. Care pathways for large or complicated lesions
    Purpose: Plan staged closure or grafting when conservative care is unsafe.
    Mechanism: Early surgical input reduces risks like hemorrhage or meningitis when bone/dura are involved. NCBI

---

Drug treatments

ACC itself has no “curative” medicine; drugs support healing and treat complications. Neonatal dosing is weight- and age-specific and must be prescribed by a clinician. Below are common, evidence-aligned choices and their roles.

1. Topical petrolatum (plain ointment) – Skin protectant/occlusive.
   Why/Mechanism: Keeps wounds moist, supports epithelial migration, lowers dressing trauma. Use: Thin layer with each dressing change. Side effects: Rare contact sensitivity. NCBI

2. Topical mupirocin – Antibacterial (anti-staphylococcal).
   Why: For small areas with crusting/impetiginization. Mechanism: Inhibits bacterial isoleucyl-tRNA synthetase. Use: Short course as directed. Side effects: Local irritation, rare resistance. NCBI

3. Topical bacitracin/polymyxin B – Broad gram-positive/gram-negative coverage.
   Why: Alternative for minor superficial infection risk. Mechanism: Cell wall/membrane disruption. Caution: Allergy risk (bacitracin); short courses only. NCBI

4. Topical fusidic acid (where available) – Anti-staphylococcal.
   Why: Localized infected erosions in regions where it’s standard. Mechanism: Inhibits bacterial protein synthesis (EF-G). Risks: Resistance with prolonged use. NCBI

5. Topical chlorhexidine (dilute, clinician-guided) – Antisepsis during dressing.
   Why: Reduce bioburden. Mechanism: Disrupts cell membranes. Caution: Neonatal skin sensitivity—use only as advised. NCBI

6. Systemic antibiotics (e.g., cephalexin, amoxicillin-clavulanate) – If cellulitis/systemic infection.
   Why: Treat spreading infection. Mechanism: Cell wall inhibition or β-lactamase-protected coverage. Side effects: GI upset, allergy; dosing per neonatology. NCBI

7. Acetaminophen (paracetamol) – Analgesic/antipyretic.
   Why: Pain control during dressing changes. Mechanism: Central COX modulation. Caution: Strict weight-based dosing; avoid overdosing. NCBI

8. Sucrose analgesia (oral, procedural) – Non-opioid procedural comfort in neonates.
   Why: Reduce short-procedure pain. Mechanism: Activates endogenous opioid pathways via taste. Use: As per neonatal protocols. NCBI

9. Topical silicone gel (after epithelialization) – Scar modulation.
   Why: May reduce hypertrophic scarring. Mechanism: Occlusion/hydration normalizes collagen. Risks: Minimal skin irritation. NCBI

10. Hydrogel dressings – Moisture-donating interface.
    Why: Support autolytic debridement and comfort. Mechanism: High water content maintains moist wound bed. Caution: Maceration if overused. NCBI

11. Silver-impregnated dressings (clinician-selected) – Antimicrobial barrier.
    Why: Reduce bioburden in selected cases. Mechanism: Silver ions disrupt bacterial enzymes. Caution: Use judiciously in neonates. NCBI

12. Topical barrier pastes (zinc oxide) – Edge protection.
    Why: Shield surrounding skin from moisture/irritants. Mechanism: Physical barrier; mild antiseptic. Risks: Minimal. NCBI

13. Topical hemostatic agents (clinician-directed) – Bleeding control if ooze occurs.
    Why: Safety near vascular scalp. Mechanism: Promotes clotting locally. Caution: Only with medical supervision. NCBI

14. Prophylactic tetanus measures – Per neonatal and maternal status.
    Why: Standard wound care practice. Mechanism: Immunization per guidelines via maternal antibodies/infant schedule. Clinician-directed. NCBI

15. Emollients after healing – Skin barrier support.
    Why: Reduce dryness/itch; protect new skin. Mechanism: Occlusive film reduces transepidermal water loss. NCBI

16. EB-specific wound protocols (if EB-CAS)
    Why: Minimize blistering beyond ACC area. Mechanism: Low-trauma lancing of tense blisters, soft padding, and antimicrobial stewardship. DermNet®

17. Antiseptic soaks (clinician-guided, dilute)
    Why: Lower bacterial load during flare. Mechanism: Osmotic/antimicrobial effect depending on solution used. Caution: Neonatal safety first. NCBI

18. Topical steroids (rare, edge dermatitis only)
    Why: Calm irritant dermatitis at wound margins. Mechanism: Anti-inflammatory effect. Caution: Avoid on open erosions; use minimal potency/duration. NCBI

19. Antireflux positioning if large chest/abdominal lesions
    Why: Limit friction/soiling. Mechanism: Keeps dressings dry and intact. NCBI

20. Antithyroid drug selection in pregnancy (prevention context)
    Why: For maternal hyperthyroidism, clinicians favor PTU in 1st trimester to reduce methimazole-linked ACC risk; decisions are individualized. Mechanism: Avoiding teratogen exposure during organogenesis. Medscape+2PubMed+2

---

Dietary molecular supplements

Supplements are not a treatment for ACC, but clinicians sometimes support wound healing with targeted nutrition if medically indicated.

1. Protein (adequate daily intake) – Provides amino acids for new tissue. Mechanism: Supports collagen and keratin synthesis; prescribed per dietetics in neonates. NCBI

2. Vitamin C (if deficient) – Cofactor for collagen hydroxylation. Mechanism: Improves collagen fiber stability during healing. NCBI

3. Zinc (if deficient) – Enzyme cofactor in DNA/protein synthesis. Mechanism: Aids epithelialization and immunity. NCBI

4. Copper (balanced trace) – Cross-linking of collagen/elastin. Mechanism: Lysyl oxidase function in extracellular matrix. NCBI

5. Arginine (specialist-directed) – Substrate for nitric oxide; supports immune function. Mechanism: May enhance collagen deposition in selected surgical/wound settings (older children/adults; neonatal use is specialist-only). NCBI

6. Omega-3 (maternal diet if breastfeeding, per pediatric advice) – Anti-inflammatory balance. Mechanism: Modulates eicosanoids; do not apply directly to wounds. NCBI

7. Vitamin A (avoid excess; only if deficient) – Epithelial health. Mechanism: Regulates keratinocyte differentiation; excess is teratogenic—never supplement in pregnancy without medical advice. NCBI

8. Iron (if deficient) – Oxygen delivery for healing tissues. Mechanism: Supports hemoglobin and cellular metabolism. NCBI

9. B-complex (if deficient) – DNA synthesis/energy metabolism. Mechanism: Supports rapidly dividing skin cells. NCBI

10. Electrolyte balance/adequate fluids – Hydration for perfusion. Mechanism: Maintains optimal cellular environment; managed by neonatology. NCBI

---

Immunity-booster/regenerative/stem-cell drugs

There are no approved “immune-booster,” regenerative, or stem-cell drugs for treating ACC in newborns. Experimental cell or growth-factor therapies are not standard of care and should only be considered within properly regulated clinical trials at specialist centers. The safest, evidence-aligned approach is meticulous wound care, infection prevention, genetic diagnosis (if syndromic), and surgery when indicated. (Below are educational notes—not recommendations):

1. Platelet-derived products (experimental) – Deliver growth factors; not neonatal standard. Mechanism: Theoretical stimulation of granulation/epithelium. Use only in trials. NCBI

2. Bioengineered skin substitutes (specialist use) – Temporary coverage for large defects. Mechanism: Acts as a scaffold/barrier; decisions individualized. NCBI

3. Cultured epithelial autografts (rare pediatric centers) – Lab-grown keratinocytes for large wounds; case-by-case. Mechanism: Provides epithelial coverage when grafts limited. NCBI

4. Topical growth factors (research only) – e.g., EGF/PDGF in other contexts; not established for neonatal ACC. Mechanism: Stimulate cell proliferation/migration. NCBI

5. Systemic “immune boosters” – Not indicated for ACC; risk > benefit. Mechanism: Non-specific; no evidence for healing gains in ACC. NCBI

6. Stem-cell infusions – Not recommended for ACC; outside evidence-based care. Mechanism: Unproven for cutaneous closure in neonates. NCBI

---

Surgeries

1. Primary surgical closure
   Procedure: Bring skin edges together and suture, sometimes with tissue undermining.
   Why: For moderate-sized scalp defects with adequate laxity to protect vessels/bone and speed healing. NCBI

2. Split-thickness skin graft (STSG)
   Procedure: Harvest thin skin from a donor site and graft onto the defect.
   Why: Cover larger areas when primary closure is unsafe or impossible. NCBI

3. Local rotation or advancement flaps
   Procedure: Rotate/advance nearby skin to cover the gap using planned incisions.
   Why: Provide durable coverage with similar color/texture while protecting deeper structures. NCBI

4. Dural repair ± cranioplasty (if skull/dura absent)
   Procedure: Neurosurgical repair of dura; later bone graft or implant for skull.
   Why: Prevent hemorrhage/infection and protect brain when deep midline scalp defects exist. NCBI

5. Tissue expansion (later childhood, selected cases)
   Procedure: Gradually expand nearby skin, then replace scar/graft area.
   Why: Improve scalp contour/hair-bearing skin for cosmetic and protective reasons. NCBI

---

Prevention tips

1. Early prenatal care to identify maternal conditions and medications that may affect fetal skin. Medscape

2. Teratogen-aware antithyroid therapy: clinicians often use PTU in 1st trimester rather than methimazole; any switch is medical-team led. Medscape+1

3. Control maternal infections (e.g., varicella) per obstetric guidance. Medscape

4. Avoid unnecessary fetal scalp instrumentation. NCBI

5. Genetic counseling for families with recessive ACC syndromes (EB-CAS, recessive AOS). PMC+1

6. Optimize maternal nutrition for fetal growth. NCBI

7. Planned delivery at a center with neonatal/dermatology support for known large lesions/syndromes. NCBI

8. Safe skin care for newborns (gentle cleansers, avoid harsh antiseptics unless prescribed). DermNet®

9. Sun protection for healing areas in infancy. DermNet®

10. Follow-up imaging/surgical consults for midline, large, or deep scalp defects. NCBI

---

When to see doctors

• Immediately/urgent: Rapid bleeding, swelling under the lesion, fever, spreading redness, foul discharge, sudden lethargy, or if dressings repeatedly soak through—especially for midline scalp lesions where large veins lie beneath. NCBI

• Soon/routine: Any new blistering or erosions beyond the original ACC (consider EB-CAS), poor weight gain, or if the area does not show gradual improvement over 1–2 weeks of good home care. DermNet®

---

What to eat and what to avoid

• Focus on: Adequate calories and protein, plus balanced micronutrients (iron, zinc, vitamin C) as advised by your pediatric team/dietitian. Breastfeeding parents can support infant nutrition with a varied, balanced diet. NCBI

• Avoid: Unnecessary supplements without medical advice; excess vitamin A in pregnancy; topical “home remedies” (herbal pastes, essential oils) on neonatal wounds, which can irritate or infect. NCBI

---

FAQs

1. Is ACC dangerous?
   Most small lesions heal well. Danger rises if the defect is large, deep, midline on the scalp, or shows signs of bleeding or infection. These need urgent assessment. NCBI

2. How common is ACC?
   Estimated around 3 per 10,000 live births (varies by study). AAP Publications

3. Is ACC always genetic?
   No. It can be isolated, teratogen-related, or part of a genetic syndrome (some recessive). Genetic evaluation is recommended when other features are present. NCBI+1

4. What are signs a syndrome might be present?
   Limb differences (AOS), skin fragility/blistering and nail changes (EB-CAS), facial patterning anomalies, or heart/vascular findings. NORD+1

5. Do all scalp defects need imaging?
   Not all. Clinicians consider imaging for large, midline, deep, or ulcer-like lesions, or when bone or dura involvement is suspected. NCBI

6. Will hair grow back?
   Small, superficial lesions often heal with a small scar that may have less hair. Large or deep lesions can leave permanent alopecia; reconstruction can improve coverage later. NCBI

7. Can dressings stick to the wound?
   Non-adherent materials and petrolatum minimize sticking and protect new skin. NCBI

8. Are topical antibiotics always needed?
   No. They’re used if crusting or early infection signs appear; otherwise simple moist care often suffices. NCBI

9. Does methimazole in pregnancy cause ACC?
   First-trimester exposure has been repeatedly associated with ACC in case series; obstetricians often prefer PTU in the first trimester when antithyroid treatment is needed. Decisions are individualized. PubMed+2Oxford Academic+2

10. Is EB-CAS always severe?
    Severity varies by EB subtype and gene. COL7A1-related recessive dystrophic EB may be more extensive; expert EB care is key. PMC

11. Is Adams–Oliver syndrome always recessive?
    No. AOS can be recessive (e.g., DOCK6/EOGT) or dominant (e.g., NOTCH1/ARHGAP31/RBPJ/DLL4). NORD

12. How long does healing take?
    Small lesions may re-epithelialize in weeks; larger ones take longer or need surgery. NCBI

13. Will my baby need antibiotics by mouth?
    Only if there is proven or strongly suspected infection spreading beyond the wound. NCBI

14. What about “stem-cell” cures?
    No approved stem-cell or “immune-booster” drugs for ACC exist; standard care is wound management and, when necessary, surgery. NCBI

15. Who should be on our care team?
    Neonatology/pediatrics, dermatology, surgery (plastic/neurosurgery for large scalp lesions), and genetics; EB centers for EB-CAS. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 20, 2025.